Arnadottir 2006.

Study characteristics
Methods	Study design: parallel, open‐label RCT Study duration: before 2006 Duration of follow‐up: 21 months in each patient
Participants	Countries: Iceland, Sweden Setting: international multicentre Inclusion criteria: biopsy‐proven IMN with nephrotic syndrome Baseline characteristics SCr (μmol/L): treatment group (107); control group (104) Use of ACEi or ARB during follow‐up: yes Number: treatment group (15); control group (15) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: not reported
Interventions	Treatment group ACTH (SC): 1.0 mg once/week, 0.75 mg twice/week or 1.0 mg twice/week for 9 months Control group No specific treatment
Outcomes	Partial or complete remission Proteinuria GFR
Notes	Abstract‐only publication Funding information: not reported Baseline characteristics: comparable Only remission data could be extracted
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	High risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	High risk	Only remission data could be extracted from the abstract
Other bias	Unclear risk	Insufficient information to permit judgement